[Development of beta 2-selective, long-acting agonists].
beta 2-Agonists have been the main bronchodilator drugs used in the symptomatic treatment of asthma. Regular use of beta 2-agonists, however, is well known to produce tolerance to their bronchoprotective effect. It has been pointed out that the over-treatment with beta 2-agonists may be associated with worsening asthma and increased risk of life-threatening attacks. To reduce the cardiovascular side effects, compounds with advanced beta 2-selectivity have been examined and established. Newly developed beta 2-selective agonists are structurally stable and long-acting. Some of them are reported to be effective for treatment of late asthmatic response, although conventional beta-agonists are thought to be relatively ineffective.